News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ocular Therapeutix, Inc. Discloses Promising Results for Extended Release Treatment of Glaucoma



7/24/2012 10:01:01 AM

BEDFORD, Mass., July 23, 2012 /PRNewswire/ -- Ocular Therapeutix, Inc. announced today initial results of their sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma. This travoprost punctum plug (OTX-TP1) was evaluated for the reduction of elevated intraocular pressure in subjects with open-angle glaucoma or ocular hypertension over a 30 day period.

Twenty six eyes were treated in 17 patients at the Singapore National Eye Center and the National University Hospital in Singapore. Prior to insertion of the plugs, mean intraocular pressure at baseline for the study group was recorded at 26.3 mm Hg. Intraocular pressure (IOP) decreased by 5.5 mm Hg at day-3 post-insertion, and after 30 days of treatment, mean IOP was 6.5 mm Hg below baseline. The OTX-TP1 is designed to absorb in approximately 4 to 6 weeks, and 88% of plugs were present at the day-30 visit. Plugs remaining in the nasolacrimal canal on day 30 were flushed. One patient demonstrated excessive tearing. Apart from that, there were no ocular complaints outside of normal limits, and patients were comfortable overall.

Visit

Mean IOP

(mm Hg)

Mean Reduction

from Baseline

(mm Hg / %)

Baseline

26.3

-

Day 3

20.8

5.5 / 20.9%

Day 10

19.5

6.8 / 25.9%

Day 20

20.4

5.9 / 22.4%

Day 30

19.8

6.5 / 24.7%

Results are comparable to topical brand name ophthalmic solutions, Travatan® (Alcon Laboratories, Inc.), Lumigan® (Allergan, Inc.), and Xalatan® (Pfizer, Inc.).1 However, topical administrations are plagued with issues of non-compliance, which can lead to costly and invasive surgeries, vision impairment, and even blindness. It has been reported that up to 60% of patients do not administer ophthalmic drops as directed, even though patients' perception is that they are compliant with 97% of their dosing.2 Sustained delivery travoprost punctum plugs may help to circumvent these issues of patient non-compliance by eliminating the need for daily dosing.

"This product has the ability to universally change the way we treat glaucoma," stated Shamira Perera, M.D., Principal Investigator at the Singapore National Eye Center. "Sustained release therapy could be advantageous to elderly patients who have difficulty administering drops, could help alleviate issues of non-compliance, and may be beneficial to anyone diagnosed with glaucoma who would prefer a life without the inconvenience of taking drops every day."

"Data collected from this study validate our technology's ability to provide therapeutic benefits for glaucoma patients, and we plan to extend the duration of therapy," stated Amar Sawhney, President and CEO of Ocular Therapeutix. "Phase II trials, which will be conducted later this year, will examine travoprost plugs for 60 day therapy (OTX-TP2) with a single insertion."

About Ocular Therapeutix's Travoprost Punctum Plugs:

Ocular Therapeutix's travoprost punctum plugs use the company's proprietary polyethylene glycol hydrogel technology to release travoprost in a sustained fashion. At the end of the treatment period, the plug begins to degrade, and exits the nasolacrimal system without need for removal by the physician. Each plug contains a visualization agent for retention monitoring throughout the treatment period.

About Ocular Therapeutix, Inc.:

Founded in November 2006, Ocular Therapeutix, Inc. is a privately held company based in Bedford, MA, focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology. Ocular Therapeutix uses its hydrogel technology for development of a variety of ophthalmic applications including hydrogel sealants for ocular surface protection, drug-eluting punctal plugs for treatment of various anterior segment diseases, and therapeutic agents for back-of-the-eye diseases.

1Package Inserts: Xalatan® 0.005% latanoprost ophthalmic solution, Pfizer, Woodstock, IL, USA. 2011; Lumigan® 0.01% and 0.03% bimatoprost ophthalmic solution, Allergan, Irvine, CA, USA. 2012; Travatan Z® 0.004% travoprost ophthalmic solution, Alcon, Fort Worth, Texas, USA. 2010.
2 Goldberg I. Compliance with Medical Management in Glaucoma. Asian J of Ophthalmol 2000;2(4):3-6.

SOURCE Ocular Therapeutix, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES